Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9727-9743

  Wang, Juping ^a,b   Lin, Danyi ^b   Peng, Hui ^b   Shao, Jimin ^a   Gu, Jiang ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Cancer; IgG; Proinflammatory cytokine; Promote; TLR4

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4; SMALL INTERFERING RNA; TLR4 PROTEIN, HUMAN; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOPLASM; DOWN REGULATION; ENDOTOXEMIA; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; FEMALE; GENETICS; HELA CELL LINE; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; UTERINE CERVIX TUMOR;

ANIMALS; CYTOKINES; FEMALE; HELA CELLS; HUMANS; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; UTERINE CERVICAL NEOPLASMS;

EID: 84930458221     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2359     Document Type: Article

References (59)

1. Takeda K, Kaisho T and Akira S. Toll-like receptors. Annu Rev Immunol. 2003; 21:335-376.
2. Akira S and Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4:499-511.
3. Liew FY, Xu D, Brint EK and O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immuno. 2005; 5:446-458.
4. Song WY, Wang GL, Chen LL, Kim HS, Pi LY, Holsten T, Gardner J, Wang B, Zhai WX, Zhu LH, Fauquet C and Ronald P. A receptor kinase-like protein encoded by the rice disease resistance gene, Xa21. Science. 1995; 270:1804-1806.
5. Gomez-Gomez L and Boller T. FLS2: an LRR receptor-like kinase involved in the perception of the bacterial elicitor flagellin in Arabidopsis. Mol Cell. 2000; 5:1003-1011.
6. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE and Aderem A. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci U S A. 2005; 102:9577-9582.
7. Barton G.M and Medzhitov R. Toll-like receptor signaling pathways. Science. 2003; 300:1524-1525.
8. Takeda K, Kaisho T and Akira S. Toll-like receptors. Annu Rev Immunol. 2003; 21:335-376.
9. Nishimura M and Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull. 2005; 28:886-892.
10. Werner J, Decarlo CA, Escott N, Zehbe I and Ulanova M. Expression of integrins and Toll-like receptors in cervical cancer: effect of infectious agents. Innate Immun. 2012; 18:55-69.
11. Yu L, Wang L, Li M, Zhong J, Wang Z and Chen S. Expression of toll-like receptor 4 is downregulated during progression of cervical neoplasia. Cancer Immunol Immunother. 2010; 59:1021-1028.
12. He W, Liu Q, Wang L, Chen W, Li N and Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007; 44:2850-2859.
13. Zhan Z, Xie X, Cao H, Zhou X, Zhang XD, Fan H and Liu Z. Autophagy facilitates TLR4-and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination. Autophagy. 2013; 10:257-268.
14. Qiu X, Zhu X, Zhang L, Mao Y, Zhang J, Hao P, Li G, Lv P, Li Z, Sun X, Wu L, Zheng J and Deng Y. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer Res. 2003; 63:6488-6495.
15. Niu N, Zhang J, Huang T, Sun Y, Chen Z, Yi W, Korteweg C, Wang J and Gu J. IgG Expression in Human Colorectal Cancer and Its Relationship to Cancer Cell Behaviors. PLoS One. 2012; doi: 10.1371/journal.pone.0047362.
16. Ma C, Wang Y, Zhang G, Chen Z, Qiu Y, Li J, Luo J, Huang B, Jiang C, Huang G, Wan X, Korteweg C and Gu J. IgG expression and its potential role in primary and metastatic breast cancers. Curr Mol Med. 2013; 13:429-437.
17. Zheng J, Huang J, Mao Y, Liu S, Sun X, Zhu X, Ma T, Zhang L, Ji J, Zhang Y, Yin CC and Qiu X. Immunoglobulin gene transcripts have distinct VHDJH recombination characteristics in human epithelial cancer cells. J Biol Chem. 2009; 284:13610-13619.
18. Zhu X, Wu L, Zhang L, Hao P, Zhang S, Huang J, Zheng J, Liu Y, Li W, Zhang Y, Zhou C, Zhang Y and Yin CC. Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells. Cell Mol Immunol. 2010; 7:279-286.
19. Lee G and Azadi P. Peptide mapping and glycoanalysis of cancer cell-expressed glycoproteins CA215 recognized by RP215 monoclonal antibody. International Journal of Carbohydrate Chemistry. 2012; 31:10-30.
20. Lee G, Cheung AP, Li B, Ge B and Chow PM. Molecular and immuno-characteristics of immunoglobulin-like glycoproteins in cancer cell-expressed biomarker, CA215. Immunol Invest. 2012; 41:429-446.
21. Wang J, Lin D, Peng H, Huang Y, Huang J and Gu J. Cancer-derived immunoglobulin G promotes tumor cell growth and proliferation through inducing production of reactive oxygen species. Cell Death Dis. 2013; doi: 10.1038/cddis.2013.474.
22. An H, Xu H, Zhang M, Zhou J, Feng T, Qian C, Qi R and Cao X. Src homology 2 domain-containing Inositol -5-phosphatase 1(SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism. Blood. 2005; 105:4685-4692.
23. An H, Zhao W, Hou J, Zhang Y, Xie Y, Zheng Y, Xu H, Qian C, Zhou J, Yu Y, Liu S, Feng G and Cao X. SHP-2 phosphatase negatively regulates the TRIF adaptor proteindependent type I interferon and proinflammatory cytokine production. Immunity. 2006; 25:919-928.
24. Saitoh T, Yamamoto M, Miyagishi M, Taira K, Nakanishi M, Fujita T, Akira S, Yamamoto N and Yamaoka S. A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol. 2005; 74:1507-1512.
25. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA and Karp CL. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol. 2005; 6:571-578.
26. Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ, Nicholson SE, Hilton DJ, O'Neill LA and Hertzog PJ. Suppressor of cytokine signaling 1 negatively regulates Toll like receptor signaling by mediating Mal degradation. Nat Immunol. 2006; 7:148-155.
27. Wakabayashi Y, Kobayashi M, Akashi-Takamura S, Tanimura N, Konno K, Takahashi K, Ishii T, Mizutani T, Iba H, Kouro T, Takaki S, Takatsu K and Oda Y. A protein associated with toll-like receptor4 (PRAT4A) regulates cell surface expression of TLR4. J Immunol. 2006; 177:1772-1779.
28. Husebye H, Halaas O, Stenmark H, Tunheim G, Sandanger Ø, Bogen B, Brech A, Latz E and Espevik T. Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J. 2006; 25:683-692.
29. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS and Itzkowitz SH. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007; 133:1869-1881.
30. Schmausser B, Andrulis M, Endrich S, Müller-Hermelink HK and Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol. 2005; 295:179-185.
31. Kim WY, Lee JW, Choi JJ, Choi CH, Kim TJ, Kim BG, Song SY and Bae DS. Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer. 2008; 18:300-305.
32. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T and Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006; 66:3859-3868.
33. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW and Selander KS. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate. 2007; 67:774-781.
34. Broering R, Wu J, Meng Z, Hilgard P, Lu M, Trippler M, Szczeponek A, Gerken G and Schlaak JF. Toll-like receptor-stimulated nonparenchymalliver cells can regulate hepatitis C virusreplication. J Hepatol. 2008; 48:914-922.
35. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G and Schlaak JF. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology. 2007; 46:1769-1778.
36. Ferrero RL. Innate immune recognition of the extracellular mucosal pathogen, Helicobacter pylori. Mol Immunol. 2005; 42:879-885.
37. Uno K, Kato K, Atsumi T, Suzuki T, Yoshitake J, Morita H, Ohara S, Kotake Y, Shimosegawa T and Yoshimura T. Toll-like receptor (TLR) 2 induced throughTLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2007; 293:G1004-G1012.
38. Yang R, Murillo FM, Cui H, Blosser R, Uematsu S, Takeda K, Akira S, Viscidi RP and Roden RB. Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce α interferon and TH1 immune responses via MyD88. J Virol. 2004; 78:11152-11160.
39. Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R and Engelhardt R. Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer. 1996; 32A:1712-1718.
40. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF and Chiavaroli C. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol. 2007; 563:1-17.
41. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF and Hoon DS. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther. 2008; 7:3642-3653.
42. He W, Liu Q, Wang L, Chen W, Li N and Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007; 44:2850-2859.
43. Ling GS, Bennett J, Woollard KJ, Szajna M, Fossati-Jimack L, Taylor PR, Scott D, Franzoso G, Cook HT and Botto M. Integrin CD11b Positively regulates TLR4-induced signalling pathways in dendritic cells but not inmacrophages. Nat Commun. 2014; doi: 10.1038/ncomms 4039.
44. Xia X, Cui J, Wang HY, Zhu L, Matsueda S, Wang Q, Yang X, Hong J, Songyang Z, Chen ZJ and Wang RF. NLRX1 Negatively Regulates TLR-Induced NF-kB Signaling by Targeting TRAF6 and IKK. Immunity. 2011; 34:843-853.
45. Wang D, Lou J, Ouyang C, Chen W, Liu Y, Liu X, Cao X, Wang J and Lu L. Ras-related protein Rab10 facilitates TLR4 signaling by promoting replenishment of TLR4 onto the plasma membrane. Proc Natl Acad Sci U S A. 2010; 107:13806-13811.
46. Shames BD, Selzman CH, Pulido EJ, Meng X, Meldrum DR, McIntyre RC Jr, Harken AH and Banerjee A.LPS-Induced NF-kB Activation and TNF-a Release in Human Monocytes Are Protein Tyrosine Kinase Dependent and Protein Kinase C Independent. J Surg Res. 1999; 83:69-74.
47. Wang Y, Chen T, Han C, He D, Liu H, An H, Cai Z and Cao X. Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4. Blood. 2007; 110:962-971.
48. Kawai T and Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11:373-384.
49. Iwasaki A and Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010; 327:291-295.
50. O'Neill L.A and Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007; 7:353-364.
51. Tartour E, Gey A, Sastre-Garau X, Pannetier C, Mosseri V, Kourilsky P and Fridman WH. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res. 1994; 54:6243-6248.
52. Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ and Hsieh CY. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol. 2001; 82:49-56.
53. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN and Hsieh CY. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003; 22:1517-1527.
54. Richter HE, Holley RL, Andrews WW, Owen J and Miller KB. The association of interleukin 6 with clinical and laboratory parameters of acute pelvic inflammatory disease. Am J Obstet Gynecol. 1999; 181:940-944.
55. Tjiong MY, van der Vange N, ten Kate FJ, Tjong-A-Hung SP, ter Schegget J, Burger MP and Out TA. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol. 1999; 73:285-291.
56. Hasimu A1, Ge L, Li QZ, Zhang RP and Guo X. Expressions of Tolllike receptors 3,4,7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer. 2011; 30:344-350.
57. Cheng YX, Qi XY, Huang JL, Hu M, Zhou LM, Li BS and Xu XX. Toll-like receptor 4 signaling promotes the immunosuppressive cytokine production of human cervical cancer. Eur J Gynaecol Oncol. 2012; 33:291-294.
58. Wang Y, Weng Y, Shi Y, Xia X, Wang S and Duan H. Expression and Functional Analysis of Toll-like Receptor 4 in Human Cervical Carcinoma. J Membr Biol. 2014; 247:591-599.
59. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC and Xiong H. Toll-like receptors on tumor cells facilitate evasion of Immune surveillance. Cancer Res. 2005; 65:5009-5014.